CurrentUnitedHealthcarePolicy N/A

Occipital Nerve Injections and Ablation (Including Occipital Neuralgia and Headache)

This part of the policy reviews clinical evidence for greater occipital nerve blocks (GONB), surgical treatments (neuroplasty, nerve decompression, neurectomy), radiofrequency ablation (RFA/pulsed and thermal), and neurostimulation/electrical stimulation for occipital neuralgia, chronic migraine, cervicogenic headache, and cluster headache. It summarizes findings from randomized trials, systematic reviews, meta-analyses, retrospective series, and Hayes evidence briefs.

Policy Summary

PayerUnitedHealthcare

PolicyOccipital Nerve Injections and Ablation (Including Occipital Neuralgia and Headache)

Policy CodePolicy N/A

Change TypeDefinitions added; supporting information updated

Effective DateSep 1, 2025

Next Review Date

Key ActionCarefully select patients for neuromodulation and consider using trial stimulation with ONS/PNS and base permanent implantation on trial response (e.g., ≥50% pain reduction).

POLICY UPDATE CHANGES

Definitions: Added definition of MIDAS and MSQ.

Supporting Information: Clinical Evidence and References sections updated to reflect current information.

38%Elimination after trigger-site surgery (Vincent 2019)

80-95%>50% reduction after occipital decompression (select studies)

35.7-100%ONS response range

63.5%

Mean improvement after occipital nerve RFA

254dMean duration of pain improvement after RFA

33%Repeat surgery rate in some ONS TAC cohorts

Scope and Purpose

This policy section reviews interventional procedures including greater occipital nerve blocks (GONB), surgical procedures (neuroplasty, nerve decompression, neurectomy), radiofrequency ablation (RFA) including pulsed and thermal modalities, and neurostimulation/electrical stimulation therapies (occipital nerve stimulation/ONS, peripheral nerve stimulation/PNS, and remote electrical neuromodulation/REN). Target conditions include occipital neuralgia, chronic migraine, cervicogenic headache, and cluster headache. Effective date: 2025-09-01. Coverage stance: informational.

Actionable Guidance and Provider Impact

Documentation Required

Evidence limitations and patient selection

Many neuromodulation therapies have low-quality or heterogeneous evidence; careful patient selection is emphasized (e.g., use of trial stimulation with ONS/PNS and selecting permanent implantation based on trial response such as ≥ 50% pain reduction).

Documentation Required

Follow federal/state/contractual benefit terms

When deciding coverage, reference applicable federal, state or contractual requirements for benefit plan coverage because they govern in the event of a conflict with this policy.

Documentation Required

Use of third-party clinical criteria

UnitedHealthcare may use third-party tools such as InterQual criteria to assist in administering benefits; providers should be prepared to supply documentation to meet such criteria.

Documentation Required

Special arrangements / research governance for neuromodulation

Per NICE and other guideline summaries, procedures like transcutaneous stimulation, occipital nerve stimulation, and SPG stimulation should be performed with special arrangements for clinical governance, consent, audit or research and outcome data collection.

Summary of Clinical Evidence

The body of evidence is generally small, heterogeneous, and often low-quality, which limits definitive conclusions. Included study types span randomized controlled trials (RCTs), systematic reviews and meta-analyses, retrospective and prospective observational series, and Hayes Evidence Analysis/Health Technology Assessment briefs. Many analyses note imprecision, short follow-up, variable techniques/populations, and risk of bias.

very low-to-moderateOverall quality of evidence across interventions

35.7-100%ONS response range across disorders (overall response rate)

253.9 daysMean duration of pain improvement after RFA (Abd-Elsayed et al. 2024)

33%Adverse events requiring repeat surgery in some ONS TACs cohorts

Evidence highlights (selected findings and sources):

- GONB RCTs/meta-analyses: multiple RCTs and meta-analyses report short-term reductions in pain intensity and headache days but are limited by small samples and short follow-up (examples cited in systematic reviews and RCTs).

Definitions and Clinical Context

This document compiles and summarizes published clinical evidence for interventional and surgical treatments for occipital neuralgia and headache disorders, drawing from RCTs, systematic reviews/meta-analyses, observational studies, and technology assessments. It provides descriptive findings, comparative summaries, and references to guideline and health-technology assessments, but notes important limitations: small sample sizes, heterogeneous populations and techniques, short follow-up durations, and generally low to very-low certainty of evidence for many interventions, which constrain firm clinical recommendations.

Term	Definition
{"text":"GONB","status":""},{"text":"Greater occipital nerve block — percutaneous injection of local anesthetic (often with or without steroid) targeting the greater occipital nerve for diagnostic or therapeutic purposes.","status":""}
{"text":"RFA","status":""},{"text":"Radiofrequency ablation — includes pulsed and thermal (nonpulsed) modalities intended to denervate or neuromodulate targeted nerves to reduce pain.","status":""}
{"text":"ONS","status":""},{"text":"Occipital nerve stimulation — implanted neurostimulation device targeting occipital nerves for refractory headache disorders.","status":""}
{"text":"REN","status":""},{"text":"Remote Electrical Neuromodulation — a noninvasive device therapy evaluated for preventive migraine.","status":""}
{"text":"PNS","status":""},{"text":"Peripheral Nerve Stimulation — stimulation of peripheral nerves such as occipital or supraorbital nerves.","status":""}
{"text":"MIDAS","status":""},{"text":"Migraine Disability Assessment Test (definition added to policy).","status":""}
{"text":"MSQ","status":""},{"text":"Migraine-Specific Quality of Life Questionnaire (definition added to policy).","status":""}

Coding

The brief does not include a discrete list of billing or procedure codes for mandatory use; while some example CPT and supply codes are referenced in the source, this summary contains no contract-specific coding lists. Providers should consult their contract-specific coding tables or payer billing resources for definitive coding guidance.

Operational Considerations for Providers

Practical implications and provider actions: trial stimulation is commonly used before permanent ONS or PNS implantation, with selection for permanent implantation typically based on an adequate trial response (commonly defined in the literature as ≥ 50% pain reduction). NICE and other guideline summaries recommend that some neuromodulation and transcutaneous stimulation procedures be performed only with special arrangements for clinical governance, consent, audit or research. Because evidence quality is variable, payers may use third‑party clinical tools (for example, InterQual) when administering benefits; providers should be prepared to supply documentation to meet such criteria and to support medical necessity determinations.

Documentation Required

Trial stimulation requirement and selection threshold

Many neuromodulation therapies have low-quality or heterogeneous evidence; careful patient selection is emphasized. Use trial stimulation for ONS/PNS and select permanent implantation based on trial response.

Trial response threshold: ≥ 50% pain reduction

Policy Revision Timeline

09/01/2025revisionLatest

Definitions added for MIDAS and MSQ; supporting information and references updated; prior version archived.

archival

Prior policy version CS086.AA archived.

Policy Summary

PayerUnitedHealthcare

PolicyOccipital Nerve Injections and Ablation (Including Occipital Neuralgia and Headache)

Policy CodePolicy N/A

Change TypeDefinitions added; supporting information updated

Effective DateSep 1, 2025

Next Review Date

Key ActionCarefully select patients for neuromodulation and consider using trial stimulation with ONS/PNS and base permanent implantation on trial response (e.g., ≥50% pain reduction).

On This Page

- Surgical decompression/neurectomy evidence: systematic reviews report variable but often substantial reductions in frequency/severity; evidence is mostly observational with high risk of bias and few RCTs.

- RFA evidence: mixed results from RCTs and observational studies; some trials and reviews suggest benefit for chronic headache and occipital neuralgia but heterogeneity in technique and limited long-term data; pulsed RFA may have a better safety profile.

- Neurostimulation/ONS evidence: systematic reviews report variable response rates (wide ranges) and long‑term responder rates with notable adverse events (lead migration, hardware complications); controlled evidence is limited.

- Hayes Evidence Briefs: multiple Hayes briefs for neuroplasty, auriculotemporal nerve (ATN) decompression, and thermal RFA conclude insufficient high-quality RCT evidence to draw definitive safety/effectiveness conclusions and recommend further appraisal as evidence grows.

- REN RCT (Tepper 2023): REN reduced mean monthly migraine days (4.0 vs 1.3 placebo; therapeutic gain 2.7 days, p<0.001) with no serious device‑related adverse events.

- ONS for TACs (Veilleux 2023): mean reductions reported (intensity 26.2%, duration 31.4%, frequency 50%); responder rates ~61% non‑SUNCT/SUNA and ~67% SUNCT/SUNA; ~33% required repeat surgery.

- 10 kHz cervical SCS (Al‑Kaisy 2022): mean MMD reduction 9.3 days at 52 weeks; 60% achieved ≥30% reduction and 50% ≥50% reduction.

- Nerivio evidence (ECRI / Hayes): RCTs show acute pain relief vs sham (e.g., ~64–67% vs 26–39%); evidence rated minimal to moderate; device appears safe with few mild adverse events.

- Systematic reviews (Oliveira, Finnern, Moisset): overall low/very-low quality evidence with signals of efficacy for PRFN, cervical SCS, and ONS in select chronic migraine and occipital neuralgia cohorts; heterogeneity limits generalizability.

- Congress of Neurological Surgeons (2023): ONS may be used as a treatment option for medically refractory occipital neuralgia (Level III).

- NICE (2022): transcutaneous supraorbital nerve stimulation—adequate safety for acute treatment but limited efficacy evidence; recommend use only with special arrangements for governance/audit and research for prevention.

- VA/DoD (2023): concludes insufficient evidence to recommend for or against many neuromodulation techniques for migraine; mixed guidance on some therapies.